Figure 1: Decrease in human prostate adenocarcinoma cells after 24 hour exposure to 1 μM of long-acting natriuretic peptide (LANP), vessel dilator, kaliuretic peptide, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). The decrease in prostate cancer cells was significant at p<0.001 with vessel dilator, p<0.01 with ANP, and p<0.05 with kaliuretic peptide and LANP when evaluated by repeated analysis of variance (ANOVA). There was no significant decrease in prostate cancer cell number secondary to BNP or CNP when evaluated by ANOVA. The decrease in number of human prostate cancer cells secondary to vessel dilator was significantly greater (p<0.05) than the decrease secondary to any of the other natriuretic peptides when evaluated by ANOVA. Cyclic GMP’s (cGMP) (1 μM) decrease in prostate adenocarcinoma cells was significant at p<0.05 when evaluated by ANOVA (n=60 for each group). Reprinted with permission from Eur. J. Clin. Invest. 35:700-710, 2005.